AlphAIAlphAI — Financial news for AI agents
247wallst.com$UTHR

United Therapeutics Q3 2026: Record Revenue, EPS Miss Explained

United Therapeutics reported Q3 2026 revenue of $832.5M, beating estimates, driven by Tyvaso DPI and Orenitram growth. EPS missed at $5.71 due to a $130M R&D charge and higher taxes. The company authorized a $2B share buyback. CEO Rothblatt highlighted growth opportunities in cardiopulmonary and respiratory therapies.

Original reporting
247wallst.com
Published Nov 4, 2026, 11:31 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 7:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
United Therapeutics Q3 2026: Record Revenue, EPS Miss Explained — source image
Source · 247wallst.com
Decision brief

The 30-second read

$UTHRBearishHigh
01

Why it matters

The earnings miss is likely to trigger a sell‑off, but the revenue beat and buyback may provide support for longer‑term investors.

02

Market read

Fresh earnings data with material surprise elements; traders can act on the immediate price impact.

03

What to watch

The $2B share buyback authorization and strong pipeline outlook may offset short‑term EPS disappointment.

Relevance 8/10Novelty 9/10Timing: after-hours

Background

United Therapeutics announced Q3 2026 results, highlighting record revenue, EPS miss, a large tax charge, and a new $2B share repurchase program.

Company-level read

Ticker impact

$UTHRBearishHigh confidence
Context

United Therapeutics reported Q3 2026 record revenue of $832.5M but GAAP EPS missed at $5.71 vs $6.04 consensus.

Expected impact

downward pressure as market prices in the EPS miss and higher effective tax rate.

Evidence & confidence

The surprise $130M tax charge and EPS shortfall are material and likely to weigh on the stock immediately.

Market effects

Sector

Biotech/therapeutics sector may see broader scrutiny of tax and acquisition accounting impacts.

Regional

U.S. biotech stocks could face short‑term volatility following the earnings miss.

Global

Limited; impact confined to U.S. listed biotech investors.

Counterpoint

What could challenge this read

Revenue beat and new share repurchase program could support the stock if investors focus on growth narrative.

Key entities

  • company
    United Therapeutics

    U.S. biotech firm focused on pulmonary and organ‑replacement therapies.

  • executive
    Martine Rothblatt

    CEO of United Therapeutics.

Read at source← All news

StoryUnited Therapeutics posts record Q3 2026 revenue but EPS miss amid higher R&D spend

Also covered by

5 outlets

Related articles

$UTHRHighAI 8/10

United Therapeutics Earnings Call Signals Stronger Growth

United Therapeutics (UTHR) reported record Q3 revenue of $833M, driven by Tyvaso's strong performance. Management highlighted growth opportunities, pipeline advancements, and intellectual property wins, but noted regulatory delays and supply chain concerns. Tyvaso revenue reached $504M, with increased patient starts and higher-dose adoption. The company expects future growth from nebulized Tyvaso and ralinepag.

tipranks.com
$UTHRHighAI 8/10

United Therapeutics Corporation Q3 2026 Earnings Call Summary

United Therapeutics reported Q3 2026 revenue of $833 million, driven by Tyvaso demand. The company is expanding into cardiopulmonary and respiratory medicine, targeting 1 million patients. Management expects growth from Tyvaso and ralinepag, with 14 programs in development. Delays include the Soft Mist Inhaler NDA filing and API supplier compliance issues. The Liquidia settlement removes a competitor from the PH-ILD market, providing Tyvaso a growth opportunity.

finance.yahoo.com